Carl Zeiss Meditec AG (LTS:0DHC) Long-Term Capital Lease Obligation : €0 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Carl Zeiss Meditec AG Long-Term Capital Lease Obligation?

Carl Zeiss Meditec AG's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0 Mil.

Carl Zeiss Meditec AG's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 (€0 Mil) to Sep. 2023 (€134 Mil) but then declined from Sep. 2023 (€134 Mil) to Dec. 2023 (€0 Mil).

Carl Zeiss Meditec AG's annual Long-Term Capital Lease Obligation increased from Sep. 2021 (€102 Mil) to Sep. 2022 (€106 Mil) and increased from Sep. 2022 (€106 Mil) to Sep. 2023 (€134 Mil).

Carl Zeiss Meditec AG Long-Term Capital Lease Obligation Historical Data

The historical data trend for Carl Zeiss Meditec AG's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carl Zeiss Meditec AG Long-Term Capital Lease Obligation Chart

Carl Zeiss Meditec AG Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

42.83

53.09

101.93

106.32

133.88

Carl Zeiss Meditec AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	134.53	-	133.88	-

Carl Zeiss Meditec AG (LTS:0DHC) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Carl Zeiss Meditec AG Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Carl Zeiss Meditec AG's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Carl Zeiss Meditec AG (LTS:0DHC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (LTS:0DHC) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CZMWY:USA CZMWF:USA 1AFX:Italy AFXd:UK AFX:Germany AFX:Austria

Address

Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745

Website

https://www.zeiss.com

Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Carl Zeiss Meditec AG (LTS:0DHC) Headlines

No Headlines